Say Goodbye to Your Smartphone
According to Microsoft engineer Alex Kipman, “Smartphones are yesterday's news. The phone is already dead. People just haven't realized.”

And it’s all thanks to the device inside this black box…
Click here to see it in action.
John Patience Insider Alerts

Get notified the next time John Patience buys or sells Biodesix stock. Enter your email address below to get our daily insider buying and selling report.

John Patience Insider Information

Chairman of Biodesix

John Patience has served as a Director of the Company since June 2008 and Chairman of the Board since September 2020. Mr. Patience currently serves as both a Director and Chairman of the board of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) and has served in that capacity since joining the board in 2012. Mr. Patience served as a director of Ventana Medical Systems, Inc. from 1989 and as Vice Chairman from 1999 until Ventana’s acquisition by Roche in 2008. Mr. Patience also served as a director of Stericycle, Inc. (NASDAQ: SRCL) since its founding in 1989 to June 2018. Mr. Patience is also a founding partner of Crabtree Partners, a private equity investment partnership in Lake Forest, Illinois. Mr. Patience was previously a partner of a venture capital investment firm that provided both Ventana and Stericycle with early stage funding. Mr. Patience was also previously a partner at the consulting firm McKinsey & Co., Inc., specializing in health care. Mr. Patience holds a B.A. in Liberal Arts and an L.L.B. from the University of Sydney, Australia, and an M.B.A. from the University of Pennsylvania’s Wharton School of Business.

What is John Patience's net worth?

The estimated net worth of John Patience is at least $248,451.28 as of August 17th, 2021. Mr. Patience owns 58,597 shares of Biodesix stock worth more than $248,451 as of January 20th. This net worth evaluation does not reflect any other assets that Mr. Patience may own. Learn More.

How do I contact John Patience?

The corporate mailing address for Mr. Patience and other Biodesix executives is , , .

Has John Patience been buying or selling shares of Biodesix?

John Patience has not been actively trading shares of Biodesix during the last quarter. Most recently, on Thursday, November 18th, John Patience bought 9,497 shares of Biodesix stock. The stock was acquired at an average cost of $6.34 per share, with a total value of $60,210.98.

Who are Biodesix's active insiders?

Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), John Patience (Chairman), and Jack Schuler (Director).

Are insiders buying or selling shares of Biodesix?

During the last twelve months, Biodesix insiders bought shares 11 times. They purchased a total of 420,792 shares worth more than $3,046,222.45. The most recent insider tranaction occured on December, 20th when Director Charles M Watts bought 5,855 shares worth more than $25,117.95. Insiders at Biodesix own 53.4 % of the company.

Information on this page was last updated on 12/20/2021.

John Patience Insider Trading History at Biodesix

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2021Buy9,497$6.34$60,210.98View SEC Filing Icon  
8/19/2021Buy8,396$8.04$67,503.84View SEC Filing Icon  
8/17/2021Buy1,604$7.12$11,420.4858,597View SEC Filing Icon  
See Full Table

John Patience Buying and Selling Activity at Biodesix

This chart shows John Patience's buying and selling at Biodesix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biodesix Company Overview

Biodesix logo
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $4.24
Low: $4.18
High: $4.78

50 Day Range

MA: $5.42
Low: $4.09
High: $7.81

2 Week Range

Now: $4.24
Low: $4.02
High: $31.35


69,578 shs

Average Volume

125,456 shs

Market Capitalization

$114.57 million

P/E Ratio


Dividend Yield



Say Goodbye to Your Smartphone
According to Microsoft engineer Alex Kipman, “Smartphones are yesterday's news. The phone is already dead. People just haven't realized.”

And it’s all thanks to the device inside this black box…
Click here to see it in action.